St. Jude Medical introduces HD VantageView System for enhancing EP lab workflow

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the launch of the VantageView™ System in the United States and Europe. The VantageView System is a state-of-the-art, high-definition (HD) monitor that eliminates the need for multiple monitors and enhances workflow by improving the visualization of critical case information in the electrophysiology (EP) lab.

“By adding a large screen to replace several smaller screens, the VantageView System can better integrate labs and create those efficiencies.”

Rapid technology advances have resulted in more equipment requiring visual displays in the EP lab, which can potentially hinder the flow of the procedure and make it challenging for clinicians to view the right screen at the right time during a case. The VantageView System was designed to consolidate the display of information from multiple technologies into one centralized location, displaying images from mapping systems, recording systems, fluoroscopy and ultrasound, among others.

The system includes a 56 inch HD monitor that can display up to eight video images simultaneously with four times the resolution seen in standard 1080p consumer monitors. The VantageView System offers exceptional image quality with greater detail than the monitors typically used in EP labs today. In addition to enhanced image quality, the VantageView System can be seamlessly integrated with the EP lab's multiple diagnostic and treatment systems, allowing clinicians to customize screen displays and more easily view and control patient and procedure information.

"For the treatment of cardiac arrhythmias, improving procedural workflow is an important way to create efficiencies and manage the cost of delivering care," said Jane J. Song, president of the St. Jude Medical Atrial Fibrillation Division. "By adding a large screen to replace several smaller screens, the VantageView System can better integrate labs and create those efficiencies."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel gene therapy holds potential in treating patients with epilepsy